Modern companies accumulate a vast amount of customer data that can be used for creating a personalized experience. Analyzing this data is difficult and most business intelligence tools cannot cope with the volume of the data. One example is churn prediction, where the cost of retaining existing customers is less than acquiring new ones. Several data mining and machine learning approaches can be used, but there is still little information about the different algorithm settings to be used when the dataset doesn't fit into a single computer memory. Because of the difficulties of applying feature selection techniques at a large scale, Incremental Probabilistic Component Analysis (IPCA) is proposed as a data preprocessing technique. Also, we present a new approach to large scale churn prediction problems based on the mini-batch Stochastic Gradient Decent (SGD) algorithm. Compared to other techniques, the new method facilitates training with large data volumes using a small memory footprint while achieving good prediction results.

Novel strategies have been developed to reduce or to avoid the intravitreal injections (IVTs) of the antiangiogenic (ranibizumab; RBZ) and the anti-inflammatory (triamcinolone acetonide; TA) agents used to treat vitreoretinal diseases. One of the strategies include liposomes. In this study, it was evaluated the safety and efficacy of topical triamcinolone-loaded liposomes formulation (TALF) as an adjuvant to intravitreal RBZ therapy in treatment-naive patients with neovascular age related macular degeneration (nAMD). Subjects were randomly assigned to the RBZ-TALF or the RBZ-pro re nata (RBZ-PRN) group. Patients from the RBZ-TALF group were instructed to apply TALF for a 12-month period after a single dose of RBZ. Patients from the RBZ-PRN group received three monthly RBZ-IVTs. Retreatment with RBZ was considered in case of nAMD reactivation. Related to safety, non-ocular abnormalities were observed during TALF therapy. Owing to the efficacy, non-significant differences are identified in visual acuity or central foveal thickness when the RBZ-PRN and RBZ-TALF groups are compared. Importantly the average number of RBZ injections was significantly lower in the RBZ-TALF group (2.5 ± 1.4 vs 6.1 ± 1.3 IVTs; p=0004). Therefore, TALF used as an adjuvant to RBZ reduce the number of RBZ-IVTs retreatment with optimal visual and anatomic results.